CYDY CytoDyn Inc

$CYDY DR JAY THE WOUNDED, HECKLED, STUBBORN & LOYAL LONGS ARE BACKING YOU 100000% WE WILL NOT BACK DOWN‼️ ESMO🙈🫡🥳☘️✅🙌🏼

$CYDY It’s easy to get lost in the noise, but worth zooming out on why we are here. Leronlimab isn’t just another speculative asset—we are targeting a fundamental biological pathway (CCR5) that dictates metastasis and immune signaling. Look at what’s in front of us: Clinical Rigor: The CLOVER trial moved fast with a heavily pretreated population where 52% are facing their 4th line of treatment, making any signals profound. The Science: Data pointing to PD-L1 upregulation changes the conversation around unlocking checkpoint inhibitors for these patients. Execution: From ctDNA tracking to opening salvage arms, the narrative is built on hard data. We’ve watched the science hold true through years of resilience, and milestones are right around the corner. Standing by the science because the mechanism speaks for itself. Let’s see how it plays out. ☘️🔬

$CYDY I’m thinking our conference call is gonna be after ESMO and after our breakthrough designation application has been turned in‼️✅🥳🫡

$CYDY All imo Judging from JL we have good or even great data. Could be partnered quickly as trial commences leading to a pivotal p3 (finally). Key is the dose-response in this current trial. Refractory cancer may differ in how the immune system is utilized from patient to patient and at this stage of learning we are still evaluating our dose response mechanism of action on cancer JL has conducted hundreds of trials with a wealth of experience in HIV and knows we have presentable information. Very positive

$CYDY I don’t think they understand what this powerful drug is about to do‼️😝 The CCR5 receptor is the central hub to inflammatory disease and the gateway to HIV‼️😝☘️🥳🫡🙈✅

$CYDY just one day I would like to see the stock green up about a dollar can I have an amen

$CYDY 🍀🍀October 25 is my birthday and I cant think of a better present than waking up to find that we have completely knocked it out of the park in mCRC. What a great omen!! LFG!! 🍀🍀

$CYDY I’m so ready for Leronlimab to be unleashed on the world. Think of the lives saved! I‘m ready for Dr‘s Jay and Pestell to be on the cover of Time and Newsweek magazines. For Senate hearings to find out who got to Amarex and Why the CD-12 COVID Trial was sabotaged by the FDA. I’m ready to buy Mazzzzzy a drink in Las Vegas so I can say I’ve looked evil in the eye.

$CYDY Seems to me that the company is getting all their ducks in a row for some future event!!!

$CYDY The significance of the clues we’ve been discussing is that they provide circumstantial evidence independent of the silence: 1) the board saying management met/exceeded goals involving significant development toward strategic partnerships/supply agreements; 2) management publicly saying it is talking with potential strategic partners; 3) BIO-Europe partnering meetings being planned; 4) the upcoming October CLOVER data; 5) and the company emphasizing partnerships as a core strategic objective. That combination is why I think it is reasonable to say substantive partnership discussions are quite plausible.

$CYDY Good morning Longs! On the doorstep of the most important October in our journey. Godspeed CYDY! 🙏🍀💥➡️

$CYDY Of course, companies with mediocre data do not behave like what we’ve seen… and will soon see. When data is weak or marginal, companies typically avoid major conferences, late‑breaking abstract windows, Breakthrough Therapy submissions, escalating doses, expanding investigator‑initiated trials, hiring or retaining high‑profile CMOs, capital‑structure cleanup, partnership discussions, and biomarker‑heavy presentations. Cytodyn has done the opposite on every one of these points. This is not how a company behaves when it expects “above average” results. This is how a company behaves when it expects compelling results.

$CYDY Closing the week with another BUY! Thanks for the discount and have a great weekend Longs!! 🙏🍀💥➡️

$CYDY this 10k is more like it! Nothing damaging. With our past history, placing such language in an SEC document, to justify bonuses and such, is telling in itself. Trial Data will be what takes the top off of this volcano! 🌋 🙏🏼💪🏼💉🤩

$CYDY By the way, I notice they still have the same guy working on the Sentiment Meter. Very -

$CYDY Ladies of Leronlimab & 9/11/2026 Mr. Hoffman just said Nov., our 5 ladies are alive 6 years: ROCK ON LADIES OF LERONLIMAB !!!!! 9/11/2026, we had our 1st Alzheimers fully completed their Leronlimab regiment. With what should also now be a very good % of additional patients having completed ROCK ON ALZHEIMERS PATIENTS !!! ...

$CYDY Very comfortable and satisfied with my HUGE position! Some days it’s nice to sit back and just watch as this miracle molecule advances towards helping millions and millions of people , let’s not lose sight of that goal OCTOBER IS JUST AROUND THE CORNER ‼️🥳 VERY, VERY, VERY 

$CYDY Its so funny the sentiment is bearish when the company has never been in as good of a position as its in now. Cash in the bank, data readouts pending, partnerships and/or acquirers queud up, operations lean, ship checked and rechecked, and they’ve cleaned up all of the old messes left behind by prior management. Bearish? Yeh right!!! This thing is wound so tight, I can’t wait to see what kind of power gets released when “The Time” comes! Hold on gang, we’re almost there!!!!

$CYDY mCRC data & .25 warrants = $95M+Followed by some FDA clarity = iP value & NASDAQ qualified OR NYSE.... Whichever wins the listing battle for humanities non-toxic Leronlimab ...

$CYDY Oh!… and companies do not issue performance‑based equity unless they believe they have something special… (see today’s 8-K)